Cancer Research

Triple-negative breast cancer remains a significant therapeutic challenge due to its aggressive nature and the absence of common hormonal receptors. Because patients lack estrogen, progesterone, and HER2 receptors, standard endocrine therapies and HER2-targeted treatments are ineffective, leaving

Recent spectroscopy and microscopy data confirm that functionalized iron oxide particles can reach a final size of 317 nm after being loaded with chemotherapy drugs. This development marks a significant milestone in the quest to refine leukemia treatments, particularly in regions where traditional

Data derived from the Phase 3 C-POST trial provided the empirical foundation for a new dosing strategy that aims to lower the physical and emotional strain of frequent cancer treatments. This recommendation from the Committee for Medicinal Products for Human Use marks a pivotal shift in how

The landscape of modern oncology is rapidly shifting toward molecular precision, leaving behind the era of broad treatments that often fail to address specific genetic drivers. Patients with P-loop and alpha-C helix compressing mutations have long lacked targeted front-line options, often falling

A dual-action strategy utilizing small interfering RNA and small activating RNA provides a sophisticated framework for correcting the molecular imbalances found in complex human tumors. This innovative methodology represents a fundamental shift in modern oncology, moving away from universal,

A significant challenge in oncology is that nearly one-quarter of breast cancer diagnoses involve aggressive HER2-positive tumors that require immediate and effective neoadjuvant therapy. This aggressive subtype is defined by an overabundance of the HER2 protein, which promotes the rapid growth of